CRA Phase I-IV Clinical Trials 3

Question 1

In a first-in-human Phase I oncology trial using the 3+3 dose escalation design, the first cohort of 3 patients shows 1 dose-limiting toxicity (DLT). What happens next?

Accepted Answer

Enroll 3 additional patients at the same dose level

Answer

In the 3+3 design, one DLT in three patients triggers enrollment of three additional patients at the same dose before deciding on escalation or de-escalation.

Question 2

What is the primary objective of a pharmacokinetic (PK) study conducted as part of a Phase I trial?

Accepted Answer

To characterize absorption, distribution, metabolism, and excretion of the drug

Answer

Phase I PK studies characterize the ADME profile to understand how the body processes the drug and to inform dosing regimens.

Question 3

A Phase III randomized controlled trial uses a double-blind design. Who in the trial is kept unaware of treatment assignment?

Accepted Answer

Both the subjects and the investigators

Answer

In a double-blind design, both subjects and investigators are unaware of treatment assignment to minimize bias in outcome assessment and reporting.

Question 4

Which of the following best describes an 'adaptive seamless Phase II/III design'?

Accepted Answer

A trial that combines Phase II and Phase III patient data in a single analysis

Answer

An adaptive seamless Phase II/III design combines both phases into a single trial, and data from both stages may contribute to the final confirmatory analysis.

Question 5

In the context of Phase IV commitments, what is a 'required post-marketing study' (RPMS)?

Accepted Answer

A study the FDA requires as a condition of drug approval

Answer

An RPMS is mandated by the FDA as a condition of approval, typically to evaluate a safety concern not fully characterized during pre-approval studies.

(CRA) Certified Research Associate Practice Test

(CRA) Certified Research Associate Practice Test

CRA Phase I-IV Clinical Trials 3